ContextLogic Inc - Ordinary Shares - Class A
LOGC - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$631.4M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $631.40 Million |
|---|---|
| Enterprise Value | $834.50 Million |
| Earnings per Share | $-1.09 |
| Beta | 2.11 |
| Outstanding Shares | 45,753,000 |
Return
| Return on Equity | 3.33% |
|---|---|
| Return on Assets | 0.96% |
| Return on Invested Capital | -2.58% |
Valuation & Multiples
| P/E Ratio | -23.79 |
|---|---|
| PEG | -4.17 |
| Price to Sales | 7.0 |
| Price to Book Ratio | 0.93 |
| Enterprise Value to Revenue | 8.5 |
| Enterprise Value to EBIT | -34.61 |
| Enterprise Value to Net Income | 90 |
| Total Debt to Enterprise | 0.26 |
| Debt to Equity | 0.76 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 9, 2026
EPS
-$0.29
Est. -$0.04Revenue
$32.20 M
Est. $32.20 MNext Earnings Call
Expected Date
March 11, 2027
EPS Estimate
-$0.04
Consensus analyst estimateRevenue Estimate
$22.34 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 2.39%▲ 2.22% |
|---|---|
| Total Invested | $4.85M▲ 1828.26% |
| Investors Holding | 2▲ 1.00% |
About LogicBio Therapeutics Inc
39 employees
CEO: Frederic Chereau
LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood. The company's proprietary GeneRide™ platform is a...